Aprea Therapeutics私募股权定价为560万美元

2026-01-29 21:52

Aprea Therapeutics (NASDAQ: APRE) said on Thursday that it has entered into a securities purchase agreement with new and existing healthcare-focused institutional investors, as well as certain insiders, to sell an aggregate of 6.29M shares of common stock.
The offering also includes warrants to purchase up to 6.29M shares of common stock and is being conducted at-the-market under Nasdaq rules.
Each share and accompanying warrant is priced at $0.89. The warrants, exercisable immediately at $0.765, expire two years after the registration statement becomes effective.
Net proceeds from the offering will be used for general corporate purposes and research and development expenses.
The offering is expected to close on January 30, 2026.
Maxim Group is acting as the sole placement agent in connection with the offering.
Shares -7.83%.

More on Aprea Therapeutics